Tafalgie Therapeutics :
A Novel Pharmaceutical Approach to Pain Treatment
Our project
Tafalgie Therapeutics is an early-stage Biotech company focusing on the development of next-generation analgesics.
Tafalgie Therapeutics is a spin-off from the CNRS / Aix-Marseille University IBDM laboratory specializing in the development of next-generation pain-relieving peptides without the disabling adverse effects of opioids. It was set up following the discovery of a novel mechanism of action for the analgesic effect of a secreted endogenous protein, TAFA4, based on modulation of the pain signal between the peripheral sensory neurons and the central nervous system.
The future first-in-class analgesic peptides developed by Tafalgie Therapeutics should be able to relieve and prevent acute and chronic pain, with no loss of efficacy over time and with far fewer adverse effects than are observed for most currently used anagesics (e.g., anxiety, respiratory problems, dizziness).
These peptides should clearly act as disease modifiers capable of blocking the mechanisms of pain initiation.
Mission
Latest News
Values
The Tafalgie team is united by a shared vision and values
Integrity:
Achieving the best level of evidence
Safety:
Reducing adverse effects
Excellence:
Fruitful collaboration between researchers, clinicians, and industry
TOWARDS BETTER HEALTH FOR ALL
Tafalgie was founded with two guiding principles:
- Ensuring the highest level of scientific proof for our molecules in terms of their efficacy, safety and all other effects
- Designing new affordable drugs, thereby ensuring that these next-generation analgesics will be accessible to everyone
TAFALGIE IS anchored IN THE MARSEILLE REGION
We aim to develop fruitful collaborations with the clinical and research ecosystem in Europe, and it is our ambition to create a new joint center of excellence for research and development in pain medication in Marseille
